NEW YORK (TheStreet) -- Leerink increased its price target on Johnson & Johnson (JNJ - Get Report) to $110, increased its estimates and set an "outperform" rating. The firm cited solid pharma momentum as the reason for the increase.
The stock was flat at $99.24 at 9:52 a.m. on Wednesday.
Must Read: Warren Buffett's 10 Favorite Growth Stocks
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts